Study reveals gaps in availability of radiotherapy services across Europe

January 23, 2013

Most strikingly, the study finds that in several countries in western Europe there are too few radiotherapy machines to ensure that cancer patients in need of radiotherapy receive treatment. For instance, in Italy around 16% of need is unmet, in Portugal 19%, Austria 20%, and the UK and Germany 21%. However, the authors caution that these apparent gaps in treatment supply may be compensated by more efficient organisation of radiotherapy provision.

Led by Eduardo Rosenblatt from the in Austria, the researchers analysed data from the Directory of Radiotherapy Centres (DIRAC) database, a global registry of radiotherapy facilities, to compare the need for radiotherapy equipment with existing supply based on the number of inhabitants and in 33 .

Availability of radiotherapy services varies widely between countries and regions within Europe. , Belgium, the Netherlands, and Switzerland are well-equipped with radiotherapy machines to meet the demand for treatment, whilst most countries in eastern and southeastern Europe are insufficiently equipped and have the greatest need to expand and modernise their equipment.

On average, the study found that countries have 5.3 teletherapy (the most common form of radiotherapy) machines per million people, but the number ranged from fewer than two per million in Macedonia and to more than eight per million in Denmark, Switzerland, Belgium, Finland, and Sweden. Overall, ten countries were found to have an insufficient number of machines to meet estimated need.

The findings suggest that fragmentation of radiotherapy services exists in 28 of the 33 countries studied, with Sweden, the UK, the Netherlands, Denmark, and Slovenia having a more centralised set-up, operating a high number (between four and ten) of machines in each centre.

"The fragmentation in radiotherapy services that prevails in many European countries might affect the of radiotherapy and its quality", say the authors, whilst emphasising that although their results do not prove whether differences in equipment and organisation have an effect on cancer outcome, they do warrant further investigation into how to optimise the efficiency of radiotherapy services.

Across Europe, cancer is on the rise. Currently, 3.2 million Europeans are diagnosed with cancer every year, with roughly half of those requiring radiotherapy at some point.

"Despite being more cost-effective than surgery and chemotherapy for treating cancer, the building and running of a radiotherapy centre requires substantial financial and technical investment, so countries need to plan ahead" , explains Rosenblatt.

"Our data should enable governments, European Union bodies, and international organisations to see at a glance how adequate the provision of radiotherapy is in each European country. For the first time, it gives countries the ability to plan investment objectively and ensure the building and maintenance of sufficient capacity to meet the ever-increasing demand", he adds.

Explore further: Treatment of rectal cancer varies enormously between different European countries

More information: www.thelancet.com/journals/lan … (12)70556-9/abstract

Related Stories

Treatment of rectal cancer varies enormously between different European countries

September 24, 2011
Stockholm, Sweden: First results from an international comparison of the care of patients with rectal cancer have shown there are substantial differences in the use of chemotherapy and radiotherapy between European countries.

Despite hype, costly prostate cancer treatment offers little relief from side effects

December 13, 2012
Prostate cancer patients receiving the costly treatment known as proton radiotherapy experienced minimal relief from side effects such as incontinence and erectile dysfunction, compared to patients undergoing a standard radiation ...

Fewer, larger radiotherapy doses prove safe for prostate cancer patients

December 13, 2011
(Medical Xpress) -- Less overall radiotherapy, delivered in fewer but higher doses, is as safe as standard, lower doses for treating prostate cancer, according to new research published in the Lancet Oncology today (Tuesday).

Sensitizing tumor cells to radiotherapy

March 1, 2012
Head and neck squamous cell carcinoma (HNSCC) is the fifth most common cancer worldwide. Tumor resistance to radio- and/or chemotherapy remains a significant clinical problem.

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.